BLU-554, A selective inhibitor of FGFR4, exhibits anti-tumour activity against gastric cancer in vitro

Fibroblast growth factor receptor 4 (FGFR4) plays a key role in cancer progression, including tumour proliferation, invasion, and metastasis. Recent studies have shown that the FGFR4 selective inhibitor BLU-554 has clinical benefits on tumour regression in hepatocellular carcinoma patients. However,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biochemical and biophysical research communications 2022-03, Vol.595, p.22-27
Hauptverfasser:	Zhang, Xiangjian, Zhang, Xinxin, Han, Ruokuo, Wang, Zhaojun, Yang, Qiuhui, Huang, Yiming, Yan, Yuxiang
Format:	Artikel
Sprache:	eng
Schlagworte:	Adaptor Proteins, Signal Transducing - metabolism Anti-tumour activity Antineoplastic Agents - pharmacology Apoptosis - drug effects BLU-554 Cell Cycle Checkpoints - drug effects Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Dose-Response Relationship, Drug FGFR4 selective inhibitor Flow Cytometry Gastric cancer Humans MAP Kinase Signaling System - drug effects Membrane Proteins - metabolism Mitogen-Activated Protein Kinase 1 - metabolism Mitogen-Activated Protein Kinase 3 - metabolism Pyrans - pharmacology Quinazolines - pharmacology RAS-RAF-MEK-ERK pathway Receptor, Fibroblast Growth Factor, Type 4 - antagonists & inhibitors Receptor, Fibroblast Growth Factor, Type 4 - metabolism Stomach Neoplasms - metabolism Stomach Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!